CONTACT US: Contact info
|
Citation |
Ricketts RW, Goza AB, Ellis CR, Singh YN, Chambers S, Singh NN, Cooke JC. J. Am. Acad. Child Adolesc. Psychiatry 1994; 33(2): 270-276. |
|
Affiliation |
Southwest Institute for Developmental Disabilities at Abilene, Texas. |
|
Copyright |
(Copyright © 1994, American Academy of Child Adolescent Psychiatry, Publisher Lippincott Williams and Wilkins) |
|
DOI |
|
PMID |
8150800 |
|
Abstract |
OBJECTIVE: The efficacy of buspirone in controlling self-injurious behavior was examined in five individuals with mental retardation. Buspirone was used alone in two individuals and as an adjunct to thioridazine in the other three. METHOD: Standard behavioral observation methods were used to collect data on the number of self-injurious responses of the individuals during baseline and several doses of buspirone in an open trial. RESULTS: When compared with baseline levels, all five individuals showed some response to buspirone, with reductions in self-injury ranging from 13% to 72%, depending on the dose. The most effective dose of buspirone was 30 mg/day for three individuals and 52.5 mg/day for the other two. These individuals were maintained for 6 to 33 weeks on their most effective dose. Coexistent symptoms of anxiety did not predict a favorable response to buspirone therapy. CONCLUSIONS: Buspirone showed a mixed but generally favorable response in controlling intractable self-injury in this and four previous studies reporting similar cases. However, the drug should not be endorsed as a proved treatment for self-injury until similar results have been obtained from well-controlled studies of its efficacy. Language: en |